The Phase I trial will evaluate the safety, tolerability and immunogenicity of Reliance’s vaccine for Covid-19. Credit: torstensimon / Pixabay.

Reliance Life Sciences has obtained approval from the Drugs Controller General of India (DCGI) to carry out a Phase I clinical trial of its Covid-19 vaccine with some conditions.

This trial will assess the safety, tolerability and immunogenicity of the two-dose vaccine against Covid-19 infection in healthy subjects, PTI reported.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The maximum tolerated dose of the vaccine will also be analysed in the Phase I trial that usually lasts for 58 days.

The latest development comes after the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) recommended initiation of Phase I trials of the SARS-CoV-2 recombinant Covid vaccine candidate, CNBC-TV18 had reported.

As per the DCGI conditions, Reliance needs to submit the updated clinical trial protocol for immunogenicity to be evaluated on day 42, rather than 14, as recommended by the SEC.

The trial will be carried out at eight centres in the Indian state of Maharashtra.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The development of Reliance’s recombinant protein-based vaccine reportedly began in 2020.

So far, the DCGI granted emergency use authorisation to six Covid-19 vaccines, namely Covishield of Serum Institute of India (SII), Covaxin of Bharat Biotech, ZyCoV-D of Zydus Cadila, Russia’s Sputnik V and the vaccines of Moderna as well as Johnson & Johnson.

Zydus Cadila’s plasmid deoxyribonucleic acid (DNA) vaccine, ZyCoV-D, for Covid-19 is developed under the country’s ‘Mission COVID Suraksha’ in collaboration with the Department of Biotechnology, Government of India and executed by Biotechnology Industry Research Assistance Council (BIRAC).

ZyCoV-D is the first-ever plasmid DNA vaccine for Covid-19 in the world, the company noted.

In June, the DCGI granted approval to the SII to produce Russia’s Covid-19 vaccine, Sputnik V, in the country.